276 related articles for article (PubMed ID: 35190936)
21. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Darwich A; Pozzi C; Fornasa G; Lizier M; Azzolini E; Spadoni I; Carli F; Voza A; Desai A; Ferrero C; Germagnoli L; ; Mantovani A; Rescigno M
EMBO Mol Med; 2022 May; 14(5):e15326. PubMed ID: 35393790
[TBL] [Abstract][Full Text] [Related]
22. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
23. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals.
Galeota E; Bevilacqua V; Gobbini A; Gruarin P; Bombaci M; Pesce E; Favalli A; Lombardi A; Vincenti F; Ongaro J; Fabbris T; Curti S; Martinovic M; Toccafondi M; Lorenzo M; Critelli A; Clemente F; Crosti M; Sarnicola ML; Martinelli M; La Sala L; Espadas A; Donnici L; Borghi MO; De Feo T; De Francesco R; Prati D; Meroni PL; Notarbartolo S; Geginat J; Gori A; Bandera A; Abrignani S; Grifantini R
Clin Immunol; 2024 Apr; 261():110164. PubMed ID: 38417765
[TBL] [Abstract][Full Text] [Related]
24. Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration.
Mihaylova A; Lesichkova S; Baleva M; Nikolova-Vlahova M; Kundurzhiev T; Kolevski A; Naumova E
J Med Virol; 2023 Jan; 95(1):e28360. PubMed ID: 36448089
[TBL] [Abstract][Full Text] [Related]
25. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
[TBL] [Abstract][Full Text] [Related]
26. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
27. A FluoroSpot B assay for the detection of IgA and IgG SARS-CoV-2 spike-specific memory B cells: Optimization and qualification for use in COVID-19 vaccine trials.
Bisceglia H; Barrier J; Ruiz J; Pagnon A
J Immunol Methods; 2023 Apr; 515():113457. PubMed ID: 36914088
[TBL] [Abstract][Full Text] [Related]
28. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
31. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
[TBL] [Abstract][Full Text] [Related]
32. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV.
Lv Z; Lv S; Li Q; Xia Y; Feng Z; Zhang H; Yang H; Wu Z; Zou N; Mo Q; Gu Q; Ying S; Wang X; Qin D; Wan C
Front Immunol; 2023; 14():1264160. PubMed ID: 38045691
[TBL] [Abstract][Full Text] [Related]
33. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
34. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
35. Elevated CD21
Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
[TBL] [Abstract][Full Text] [Related]
36. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
37. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
Tanaka H; Mukai J; Kushibiki K; Mizushima S; Maeda K; Fujimoto Y; Sawada R; Oda M; Okuda H; Yamaki M; Hashiguchi S; Kawai I; Kawaguchi I; Masuda N; Matsushita H
Vaccine; 2023 Jan; 41(2):365-371. PubMed ID: 36460533
[TBL] [Abstract][Full Text] [Related]
38. Increase in SARS-CoV-2 RBD-Specific IgA and IgG Antibodies in Human Milk From Lactating Women Following the COVID-19 Booster Vaccination.
Henle AM
J Hum Lact; 2023 Feb; 39(1):51-58. PubMed ID: 36398916
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
40. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients.
Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC
Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
